vs
阿特拉斯·科普柯（AESI）与REPLIGEN CORP（RGEN）财务数据对比。点击上方公司名可切换其他公司
阿特拉斯·科普柯的季度营收约是REPLIGEN CORP的1.3倍（$249.4M vs $197.9M），REPLIGEN CORP净利率更高（6.7% vs -8.9%，领先15.6%），REPLIGEN CORP同比增速更快（13.6% vs -8.1%），REPLIGEN CORP自由现金流更多（$17.6M vs $-18.1M），过去两年REPLIGEN CORP的营收复合增速更高（14.4% vs 13.8%）
阿特拉斯·科普柯集团是瑞典跨国工业企业，生产压缩机、真空设备、泵、发电机、装配工具、质量检测设备等工业应用及移动发电领域的产品与系统，业务覆盖全球约180个国家。
Repligen是一家全球生命科学企业，专注于创新生物工艺技术与系统的研发及商业化，助力提升生物药生产效率。公司1981年成立，总部位于美国马萨诸塞州沃尔瑟姆，于纳斯达克挂牌上市，股票代码RGEN，截至2025年全球员工超1900人，主要服务生物制药领域客户。
AESI vs RGEN — 直观对比
营收规模更大
AESI
是对方的1.3倍
$197.9M
营收增速更快
RGEN
高出21.7%
-8.1%
净利率更高
RGEN
高出15.6%
-8.9%
自由现金流更多
RGEN
多$35.7M
$-18.1M
两年增速更快
RGEN
近两年复合增速
13.8%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $249.4M | $197.9M |
| 净利润 | $-22.2M | $13.3M |
| 毛利率 | 8.1% | 52.5% |
| 营业利润率 | -6.0% | 9.0% |
| 净利率 | -8.9% | 6.7% |
| 营收同比 | -8.1% | 13.6% |
| 净利润同比 | -254.5% | 143.9% |
| 每股收益（稀释后） | $-0.19 | $0.24 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AESIRGEN
| Q4 25 | $249.4M | $197.9M | ||
| Q3 25 | $259.6M | $188.8M | ||
| Q2 25 | $288.7M | $182.4M | ||
| Q1 25 | $297.6M | $169.2M | ||
| Q4 24 | $271.3M | $174.1M | ||
| Q3 24 | $304.4M | $154.9M | ||
| Q2 24 | $287.5M | $154.1M | ||
| Q1 24 | $192.7M | $151.3M |
净利润AESIRGEN
| Q4 25 | $-22.2M | $13.3M | ||
| Q3 25 | $-23.7M | $14.9M | ||
| Q2 25 | $-5.6M | $14.9M | ||
| Q1 25 | $1.2M | $5.8M | ||
| Q4 24 | $14.4M | $-30.3M | ||
| Q3 24 | $3.9M | $-654.0K | ||
| Q2 24 | $14.8M | $3.3M | ||
| Q1 24 | $26.8M | $2.1M |
毛利率AESIRGEN
| Q4 25 | 8.1% | 52.5% | ||
| Q3 25 | 9.2% | 53.2% | ||
| Q2 25 | 18.1% | 50.0% | ||
| Q1 25 | 18.3% | 53.6% | ||
| Q4 24 | 18.4% | 26.1% | ||
| Q3 24 | 17.4% | 50.0% | ||
| Q2 24 | 21.0% | 49.8% | ||
| Q1 24 | 35.7% | 49.5% |
营业利润率AESIRGEN
| Q4 25 | -6.0% | 9.0% | ||
| Q3 25 | -7.1% | 8.9% | ||
| Q2 25 | 2.5% | 7.6% | ||
| Q1 25 | 5.2% | 3.9% | ||
| Q4 24 | 11.3% | -17.7% | ||
| Q3 24 | 5.0% | -5.1% | ||
| Q2 24 | 9.8% | 1.0% | ||
| Q1 24 | 20.6% | 1.3% |
净利率AESIRGEN
| Q4 25 | -8.9% | 6.7% | ||
| Q3 25 | -9.1% | 7.9% | ||
| Q2 25 | -1.9% | 8.2% | ||
| Q1 25 | 0.4% | 3.4% | ||
| Q4 24 | 5.3% | -17.4% | ||
| Q3 24 | 1.3% | -0.4% | ||
| Q2 24 | 5.2% | 2.2% | ||
| Q1 24 | 13.9% | 1.4% |
每股收益（稀释后）AESIRGEN
| Q4 25 | $-0.19 | $0.24 | ||
| Q3 25 | $-0.19 | $0.26 | ||
| Q2 25 | $-0.04 | $0.26 | ||
| Q1 25 | $0.01 | $0.10 | ||
| Q4 24 | $0.12 | $-0.55 | ||
| Q3 24 | $0.04 | $-0.01 | ||
| Q2 24 | $0.13 | $0.06 | ||
| Q1 24 | $0.26 | $0.04 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $767.6M |
| 总债务越低越好 | $604.2M | $542.2M |
| 股东权益账面价值 | $1.2B | $2.1B |
| 总资产 | $2.2B | $2.9B |
| 负债/权益比越低杠杆越低 | 0.50× | 0.26× |
8季度趋势，按日历期对齐
现金及短期投资AESIRGEN
| Q4 25 | — | $767.6M | ||
| Q3 25 | — | $748.7M | ||
| Q2 25 | — | $708.9M | ||
| Q1 25 | — | $697.2M | ||
| Q4 24 | — | $757.4M | ||
| Q3 24 | — | $784.0M | ||
| Q2 24 | — | $809.1M | ||
| Q1 24 | — | $780.6M |
总债务AESIRGEN
| Q4 25 | $604.2M | $542.2M | ||
| Q3 25 | $529.1M | $537.9M | ||
| Q2 25 | $533.8M | — | ||
| Q1 25 | $538.5M | — | ||
| Q4 24 | $0 | $525.6M | ||
| Q3 24 | $180.0M | — | ||
| Q2 24 | $180.0M | — | ||
| Q1 24 | $180.0M | — |
股东权益AESIRGEN
| Q4 25 | $1.2B | $2.1B | ||
| Q3 25 | $1.2B | $2.1B | ||
| Q2 25 | $1.3B | $2.1B | ||
| Q1 25 | $1.3B | $2.0B | ||
| Q4 24 | $1.0B | $2.0B | ||
| Q3 24 | $1.0B | $2.0B | ||
| Q2 24 | $1.1B | $2.0B | ||
| Q1 24 | $1.1B | $2.0B |
总资产AESIRGEN
| Q4 25 | $2.2B | $2.9B | ||
| Q3 25 | $2.2B | $2.9B | ||
| Q2 25 | $2.2B | $2.9B | ||
| Q1 25 | $2.3B | $2.9B | ||
| Q4 24 | $2.0B | $2.8B | ||
| Q3 24 | $2.0B | $2.8B | ||
| Q2 24 | $2.0B | $2.9B | ||
| Q1 24 | $1.9B | $2.8B |
负债/权益比AESIRGEN
| Q4 25 | 0.50× | 0.26× | ||
| Q3 25 | 0.43× | 0.26× | ||
| Q2 25 | 0.42× | — | ||
| Q1 25 | 0.41× | — | ||
| Q4 24 | 0.00× | 0.27× | ||
| Q3 24 | 0.17× | — | ||
| Q2 24 | 0.17× | — | ||
| Q1 24 | 0.17× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $3.7M | $25.7M |
| 自由现金流经营现金流 - 资本支出 | $-18.1M | $17.6M |
| 自由现金流率自由现金流/营收 | -7.3% | 8.9% |
| 资本支出强度资本支出/营收 | 8.7% | 4.1% |
| 现金转化率经营现金流/净利润 | — | 1.93× |
| 过去12个月自由现金流最近4个季度 | $-30.9M | $93.9M |
8季度趋势，按日历期对齐
经营现金流AESIRGEN
| Q4 25 | $3.7M | $25.7M | ||
| Q3 25 | $32.4M | $48.1M | ||
| Q2 25 | $88.6M | $28.6M | ||
| Q1 25 | $-7.5M | $15.0M | ||
| Q4 24 | $70.9M | $39.2M | ||
| Q3 24 | $85.2M | $49.3M | ||
| Q2 24 | $60.9M | $42.2M | ||
| Q1 24 | $39.6M | $44.7M |
自由现金流AESIRGEN
| Q4 25 | $-18.1M | $17.6M | ||
| Q3 25 | $-1.4M | $43.4M | ||
| Q2 25 | $48.4M | $21.5M | ||
| Q1 25 | $-59.8M | $11.4M | ||
| Q4 24 | $-5.6M | $33.6M | ||
| Q3 24 | $-1.1M | $42.3M | ||
| Q2 24 | $-54.9M | $37.4M | ||
| Q1 24 | $-55.9M | $36.4M |
自由现金流率AESIRGEN
| Q4 25 | -7.3% | 8.9% | ||
| Q3 25 | -0.5% | 23.0% | ||
| Q2 25 | 16.8% | 11.8% | ||
| Q1 25 | -20.1% | 6.8% | ||
| Q4 24 | -2.1% | 19.3% | ||
| Q3 24 | -0.4% | 27.3% | ||
| Q2 24 | -19.1% | 24.3% | ||
| Q1 24 | -29.0% | 24.0% |
资本支出强度AESIRGEN
| Q4 25 | 8.7% | 4.1% | ||
| Q3 25 | 13.0% | 2.5% | ||
| Q2 25 | 13.9% | 3.9% | ||
| Q1 25 | 17.6% | 2.1% | ||
| Q4 24 | 28.2% | 3.2% | ||
| Q3 24 | 28.3% | 4.5% | ||
| Q2 24 | 40.3% | 3.1% | ||
| Q1 24 | 49.6% | 5.5% |
现金转化率AESIRGEN
| Q4 25 | — | 1.93× | ||
| Q3 25 | — | 3.23× | ||
| Q2 25 | — | 1.92× | ||
| Q1 25 | -6.11× | 2.57× | ||
| Q4 24 | 4.92× | — | ||
| Q3 24 | 21.74× | — | ||
| Q2 24 | 4.10× | 12.70× | ||
| Q1 24 | 1.48× | 21.35× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
AESI
| Services | $126.2M | 51% |
| Products | $105.2M | 42% |
| Moser Acquisition | $18.1M | 7% |
RGEN
暂无分部数据
